Drug Reprograms Immune Responses to Target Glioblastoma
Investigators have discovered that using a novel drug agonist to target the STING pathway in preclinical models of glioblastoma reprogrammed previously suppressed immune responses, according to recent findings published in the Journal of Clinical Investigation.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed